| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| BSDC1 | MARC2 | ENSSSCP00000046082 | ENSSSCP00000011541 | BSD domain containing 1. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.440 |
| BSDC1 | TAPT1 | ENSSSCP00000046082 | ENSSSCP00000019996 | BSD domain containing 1. | Transmembrane anterior posterior transformation 1. | 0.416 |
| BSDC1 | TMEM97 | ENSSSCP00000046082 | ENSSSCP00000027559 | BSD domain containing 1. | Transmembrane protein 97; Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cells. Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation. May play a role as a regulator of cellular cholesterol homeostasis. May function as sterol isomerase. May alter the activity of some cytochrome P450 proteins. | 0.778 |
| C1orf115 | MARC2 | ENSSSCP00000023310 | ENSSSCP00000011541 | Chromosome 1 open reading frame 115. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.447 |
| MARC2 | BSDC1 | ENSSSCP00000011541 | ENSSSCP00000046082 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | BSD domain containing 1. | 0.440 |
| MARC2 | C1orf115 | ENSSSCP00000011541 | ENSSSCP00000023310 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Chromosome 1 open reading frame 115. | 0.447 |
| MARC2 | MRPL41 | ENSSSCP00000011541 | ENSSSCP00000048589 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Mitochondrial ribosomal protein L41. | 0.503 |
| MARC2 | MRPS35 | ENSSSCP00000011541 | ENSSSCP00000044070 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | MRP-S28 domain-containing protein. | 0.440 |
| MARC2 | OSGEPL1 | ENSSSCP00000011541 | ENSSSCP00000050728 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Probable tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial; Required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in mitochondrial tRNAs that read codons beginning with adenine. Probably involved in the transfer of the threonylcarbamoyl moiety of threonylcarbamoyl-AMP (TC-AMP) to the N6 group of A37. Involved in mitochondrial genome maintenance. | 0.461 |
| MARC2 | SLC25A20 | ENSSSCP00000011541 | ENSSSCP00000012119 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Mitochondrial carnitine/acylcarnitine carrier protein; Belongs to the mitochondrial carrier (TC 2.A.29) family. | 0.474 |
| MARC2 | SNX19 | ENSSSCP00000011541 | ENSSSCP00000058120 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Sorting nexin-19 isoform X1. | 0.552 |
| MARC2 | SUOX | ENSSSCP00000011541 | ENSSSCP00000000396 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Sulfite oxidase, mitochondrial isoform X1. | 0.628 |
| MARC2 | TAPT1 | ENSSSCP00000011541 | ENSSSCP00000019996 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Transmembrane anterior posterior transformation 1. | 0.553 |
| MARC2 | TMEM97 | ENSSSCP00000011541 | ENSSSCP00000027559 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Transmembrane protein 97; Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cells. Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation. May play a role as a regulator of cellular cholesterol homeostasis. May function as sterol isomerase. May alter the activity of some cytochrome P450 proteins. | 0.599 |
| MRPL41 | MARC2 | ENSSSCP00000048589 | ENSSSCP00000011541 | Mitochondrial ribosomal protein L41. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.503 |
| MRPL41 | MRPS35 | ENSSSCP00000048589 | ENSSSCP00000044070 | Mitochondrial ribosomal protein L41. | MRP-S28 domain-containing protein. | 0.954 |
| MRPS35 | MARC2 | ENSSSCP00000044070 | ENSSSCP00000011541 | MRP-S28 domain-containing protein. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.440 |
| MRPS35 | MRPL41 | ENSSSCP00000044070 | ENSSSCP00000048589 | MRP-S28 domain-containing protein. | Mitochondrial ribosomal protein L41. | 0.954 |
| OSGEPL1 | MARC2 | ENSSSCP00000050728 | ENSSSCP00000011541 | Probable tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial; Required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in mitochondrial tRNAs that read codons beginning with adenine. Probably involved in the transfer of the threonylcarbamoyl moiety of threonylcarbamoyl-AMP (TC-AMP) to the N6 group of A37. Involved in mitochondrial genome maintenance. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.461 |
| SLC25A20 | MARC2 | ENSSSCP00000012119 | ENSSSCP00000011541 | Mitochondrial carnitine/acylcarnitine carrier protein; Belongs to the mitochondrial carrier (TC 2.A.29) family. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.474 |
